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ABSTRACT	2	
Background	3	
Bacillus	Calmette–Guérin	(BCG)	is	one	of	the	most	widely-used	vaccines	worldwide.	BCG	4	 primarily	reduces	the	progression	from	infection	to	disease,	however	there	is	evidence	that	5	 BCG	may	provide	additional	benefits.	We	aimed	to	investigate	whether	there	is	evidence	in	6	 routinely-collected	surveillance	data	that	BCG	vaccination	impacts	outcomes	for	7	 tuberculosis	(TB)	cases	in	England.	8	
Methods	9	
We	obtained	all	TB	notifications	for	2009-2015	in	England	from	the	Enhanced	Tuberculosis	10	 surveillance	system.	We	considered	five	outcomes:	All-cause	mortality,	death	due	to	TB	(in	11	 those	who	died),	recurrent	TB,	pulmonary	disease,	and	sputum	smear	status.	We	used	12	 logistic	regression,	with	complete	case	analysis,	to	investigate	each	outcome	with	BCG	13	 vaccination,	years	since	vaccination	and	age	at	vaccination,	adjusting	for	potential	14	 confounders.	All	analyses	were	repeated	using	multiply	imputed	data.	15	
Results	16	
We	found	evidence	of	an	association	between	BCG	vaccination	and	reduced	all-cause	17	 mortality	(aOR:0.76	(95%CI	0.64	to	0.89),	P:0.001)	and	weak	evidence	of	an	association	18	 with	reduced	recurrent	TB	(aOR:0.90	(95%CI	0.81	to	1.00),	P:0.056).	Analyses	using	19	 multiple	imputation	suggested	that	the	benefits	of	vaccination	for	all-cause	mortality	were	20	 reduced	after	10	years.	21	
		
Conclusions	1	
We	found	that	BCG	vaccination	was	associated	with	reduced	all-cause	mortality	in	people	2	 with	TB	although	this	benefit	was	less	pronounced	more	than	10	years	after	vaccination.	3	 There	was	weak	evidence	of	an	association	with	reduced	recurrent	TB.	4	
Keywords:	Tuberculosis,	BCG,	Surveillance,	Non-specific,	Mortality	5	
Highlights	6	
• Found	evidence	of	an	association	between	BCG	vaccination	and	reduced	all-cause	7	 mortality	in	TB	cases.	8	
• Weaker	evidence	of	an	association	between	BCG	vaccination	and	reduced	repeat	TB	9	 episodes	in	TB	cases.	10	
• There	was	little	evidence	of	an	association	with	other	TB	outcomes.	11	
• There	was	weak	evidence	of	associations	between	TB	outcomes	and	age	at,	or	years	12	 since,	vaccination.	13	
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INTRODUCTION	2	
Bacillus	Calmette–Guérin	(BCG)	is	one	of	the	mostly	widely-used	vaccines	and	the	only	3	 vaccine	that	protects	against	tuberculosis	(TB)	disease.	BCG	was	first	used	in	humans	in	4	 1921	and	was	introduced	into	the	WHO	Expanded	Program	on	Immunization	in	1974.[1]	5	 BCG	vaccination	has	been	controversial	due	to	its	variable	efficacy	and	possibility	of	6	 causing	a	false	positive	result	with	the	standard	skin	test	for	TB.[2]	However,	the	lack	of	a	7	 more	effective	vaccine	and	the	emergence	of	drug-resistant	TB	strains	means	that	BCG	8	 vaccination	remains	an	important	tool	for	reducing	TB	incidence	and	mortality	rates.	9	
BCG’s	primary	mode	of	action	is	to	directly	prevent	the	development	of	active,	symptomatic	10	 disease.	Its	efficacy	in	adults	is	context	specific,	with	estimates	ranging	between	0%	and	11	 78%.[3]	It	has	been	shown	to	highly	efficacious	in	England	and	there	is	some	evidence	that	12	 efficacy	increases	with	distance	from	the	equator.	Efficacy	has	been	shown	to	be	dependent	13	 on	previous	exposure,	with	unexposed	individuals	receiving	the	greatest	benefit.[4]	Unlike	14	 in	adults,	BCG	has	consistently	been	shown	to	be	highly	protective	against	TB	and	TB	15	 meningitis	in	children.[5,6]	For	this	reason	the	majority	of	countries	that	use	BCG,	16	 vaccinate	at	birth.[7,8]	Adult	vaccination	is	no	longer	common	in	the	UK,	where	universal	17	 BCG	vaccination	of	adolescents	was	stopped	in	2005	in	favour	of	a	targeted	neonatal	18	 programme	aimed	at	high	risk	children.	19	
Vaccination	policy	has	been	primarily	based	on	reducing	the	incidence	of	TB	disease,	and	20	 mitigating	disease	severity,	with	little	attention	having	been	given	to	any	additional	effects	21	 of	BCG	vaccination	on	TB	outcomes..[9,10]	There	is	some	evidence	that	BCG	vaccination	22	 induces	innate	immune	responses	which	may	provide	non-specific	protection,[11]	TB	23	
		
patients	with	BCG	scars	were	found	to	respond	better	to	treatment	with	earlier	sputum	1	 smear	conversion,[12]	and	there	is	evidence	to	suggest	that	BCG	vaccination	is	associated	2	 with	reduced	all-cause	neonatal	mortality[13,14]	and	both	reduced	TB[15]	and	all-3	 cause[16]	mortality	in	the	general	population.	Given	that	the	immunology	behind	TB	4	 immunity	is	not	fully	understood	these	findings	suggest	that	BCG	may	play	a	more	5	 important	role	in	improving	TB	outcomes	than	previously	thought.	We	aimed	to	quantify	6	 the	effects	of	BCG	vaccination	on	outcomes	for	individuals	with	notified	TB	in	England	7	 using	routinely	collected	surveillance	data	to	provide	evidence	for	appropriate	public	8	 health	action	and	provision.	Where	we	found	an	association,	we	additionally	explored	the	9	 role	of	years	since	vaccination,	and	age	at	vaccination.	10	
		
PAGEBREAK 1	
METHOD	2	
Enhanced	Tuberculosis	Surveillance	(ETS)	system	3	
We	extracted	all	notifications	from	the	Enhanced	Tuberculosis	Surveillance	(ETS)	system	4	 from	January	1,	2009	to	December	31,	2015.	BCG	vaccination	status	and	year	of	vaccination	5	 have	been	collected	since	2008.	The	outcomes	we	considered	were:	all-cause	mortality,	6	 death	due	to	TB	(in	those	who	died),	recurrent	TB,	pulmonary	disease,	and	sputum	smear	7	 status.	These	outcomes	were	selected	based	on:	their	availability	in	the	ETS;	evidence	from	8	 the	literature	of	prior	associations	with	BCG	vaccination;	associations	with	increased	case	9	 infectiousness;	or	severe	outcomes	for	patients.	10	
All-cause	mortality	was	defined	using	the	overall	outcome	recorded	in	ETS,	this	is	based	on	11	 up	to	36	months	of	follow	up	starting	from	date	of	starting	treatment.	Follow	up	ends	when	12	 a	case	is	recorded	as	completing	treatment,	with	treatment	status	evaluated	at	12,	24,	and	13	 36	months	from	starting	treatment.	Where	the	treatment	start	date	was	not	available	the	14	 notification	date	was	used	if	appropriate.	The	date	of	death	was	validated	against	Office	for	15	 National	Statistics	(ONS)	data.	Those	that	were	lost	to	follow	up,	or	not	evaluated	were	16	 treated	as	missing.	In	cases	with	a	known	cause	of	death,	death	due	to	TB	was	defined	as	17	 those	that	died	from	TB,	or	where	TB	had	contributed	to	their	death.	Cause	of	death	was	18	 recorded	by	case	managers.	TB	cases	who	had	recurrent	episodes	were	identified	using	19	 probabilistic	matching.	Positive	sputum	smear	status	was	given	to	cases	that	had	a	sputum	20	 sample	shown	to	contain	Acid-Fast	Bacilli.	A	positive	sputum	smear	status	indicates	that	21	 cases	are	more	likely	to	be	infectious.	Cases	were	defined	as	having	pulmonary	TB	if	a	22	 positive	sputum	smear	sample	was	recorded,	if	a	positive	culture	was	grown	from	a	23	
		
pulmonary	laboratory	specimen,	or	if	they	were	clinically	assessed	as	having	pulmonary	1	 TB.		2	
Exposure	variables	relating	to	BCG	3	
We	included	three	exposure	variables	related	to	BCG:	BCG	status	(vaccinated,	yes/no),	4	 years	since	vaccination	and	age	at	vaccination.	5	
BCG	status	was	collected	and	recorded	in	ETS	by	case	managers.	Information	on	BCG	6	 vaccination	status	may	have	come	from	vaccination	records,	patient	recall	or	the	presence	7	 of	a	scar.	When	cases	are	uncertain,	and	there	is	no	evidence	of	a	scar,	no	BCG	status	is	8	 given.	Year	of	vaccination	was	collected	similarly.	Years	since	BCG	vaccination	was	defined	9	 as	year	of	notification	minus	year	of	vaccination	and	categorised	into	two	groups	(0	to	10	10	 and	11+	years).	This	was	based	on:	evidence	that	the	average	duration	of	BCG	protection	is	11	 at	least	10-15	years;[15]	increasing	recall	bias	with	time	since	vaccination,	and	any	12	 association	between	years	since	vaccination	and	TB	outcomes	may	be	non-linear.	Age	at	13	 vaccination	is	defined	in	the	online	supplementary	information.	14	
Statistical	Analysis	15	
R	was	used	for	all	statistical	analysis.[17]	The	analysis	was	conducted	in	two	stages.	Firstly,	16	 we	calculated	proportions	for	all	demographic	and	outcome	variables,	and	compared	17	 vaccinated	and	unvaccinated	TB	cases	using	the	!"	test.	Secondly,	we	used	logistic	18	 regression,	with	complete	case	analysis,	to	estimate	the	association	between	exposures	and	19	 outcome	variables,	both	with	and	without	adjustment	for	confounders.	20	
		
In	the	multivariable	models,	we	adjusted	for	sex,[18–20]	age,[21]	Index	of	Multiple	1	 Deprivation	(2010)	categorised	into	five	groups	for	England	(IMD	rank),[22,23]	2	 ethnicity,[18,24]	UK	birth	status,[25,26]	and	year	of	notification.	As	the	relationship	3	 between	age	and	outcomes	was	non-linear,	we	modelled	age	using	a	natural	cubic	spline	4	 with	knots	at	the	25%,	50%	and	75%	quantiles.	5	
We	conducted	sensitivity	analyses	to	assess	the	robustness	of	the	results,	by	dropping	each	6	 confounding	variable	in	turn	and	assessing	the	effect	on	the	adjusted	Odds	Ratios	(aORs)	of	7	 the	exposure	variable.	We	repeated	the	analysis	excluding	duplicate	recurrent	cases,	and	8	 restricting	the	study	population	to	those	eligible	for	the	BCG	schools	scheme	(defined	as	UK	9	 born	cases	that	were	aged	14	or	over	in	2004)	to	assess	the	comparability	of	the	BCG	10	 vaccinated	and	unvaccinated	populations.	To	mitigate	the	impact	of	missing	data	we	used	11	 multiple	imputation,	with	the	MICE	package.[27]	We	imputed	50	data	sets	(for	20	12	 iterations)	using	all	outcome	and	explanatory	variables	included	in	the	analysis	as	13	 predictors	along	with	Public	Health	England	centre.	The	model	results	were	pooled	using	14	 the	small	sample	method,[28]	and	effect	sizes	compared	with	those	from	the	main	analysis.	15	
RESULTS	16	
Description	of	the	data	17	
There	were	51,645	TB	notifications	between	2009-2015	in	England.	Reporting	of	18	 vaccination	status	and	year	of	vaccination	improved	over	time:	64.9%	(20865/32154)	of	19	 notifications	included	vaccination	status	for	2009	to	2012,	increasing	to	70%	20	 (13647/19491)	from	2013	to	2015.	The	majority	of	cases	that	had	a	known	vaccination	21	
		
status	were	vaccinated	(70.6%,	24354/34512),	and	where	age	and	year	of	vaccination	was	1	 known,	the	majority	of	cases	were	vaccinated	at	birth	(60%,	5979/10066).	2	
Vaccinated	cases	were	younger	than	unvaccinated	cases	on	average	(median	age	34	years	3	 (IQR	26	to	45)	compared	to	38	years	(IQR	26	to	62)).	A	higher	proportion	of	non-UK	born	4	 cases	were	BCG	vaccinated,	(72.7%,	18297/25171)	compared	to	UK	born	cases	(65.2%,	5	 5787/8871,	P:	<	0.001)	and,	of	those	vaccinated,	a	higher	proportion	of	non-UK	born	cases	6	 were	vaccinated	at	birth	compared	to	UK	born	cases	(68%,	4691/6896	vs.	40.5%,	7	 1253/3096	respectively,	P:	<	0.001).	See	table	1	for	the	breakdown	of	outcome	variables	8	 table	2	for	the	breakdown	of	confounding	variables.	9	
	 	10	
		
	1	
Table	1:	Outcomes	for	individuals	in	England	notified	with	tuberculosis	between	2009-2015,	2	
stratified	by	BCG	vaccination	status.	3	
Outcome Total Vaccinated Unvaccinated Unknown vaccine 
status 
Total, all cases 51645 24354 {47} 10158 {20} 17133 {33} 
All-cause mortality 45588 (88) 21685 (89) 9061 (89) 14842 (87) 
   No    43024 [94]    21291 [98]    8495 [94]    13238 [89] 
   Yes    2564 [6]    394 [2]    566 [6]    1604 [11] 
Death due to TB (in 
those who died*) 
1373 (3) 276 (1) 320 (3) 777 (5) 
   No    572 [42]    129 [47]    146 [46]    297 [38] 
   Yes    801 [58]    147 [53]    174 [54]    480 [62] 
Recurrent TB 48497 (94) 23963 (98) 9991 (98) 14543 (85) 
   No    44869 [93]    22592 [94]    9256 [93]    13021 [90] 
   Yes    3628 [7]    1371 [6]    735 [7]    1522 [10] 
Pulmonary TB 51432 (100) 24289 (100) 10121 (100) 17022 (99) 
   Extra-pulmonary (EP) 
only 
   24280 [47]    12085 [50]    4573 [45]    7622 [45] 
		
   Pulmonary, with or 
without EP 
   27152 [53]    12204 [50]    5548 [55]    9400 [55] 
Sputum smear status 19551 (38) 9768 (40) 3910 (38) 5873 (34) 
   Negative    11060 [57]    5694 [58]    2231 [57]    3135 [53] 
   Positive    8491 [43]    4074 [42]    1679 [43]    2738 [47] 
{% all cases}(% complete within vaccine status)[% complete within category], 
 * Death due to TB in those who died and where cause of death was known 
1	
		 14	
Table	2:	Confounders	for	individuals	in	England	notified	with	tuberculosis	between	2009-1	
2015,	stratified	by	BCG	vaccination	status.		2	
Confounder Total Vaccinated Unvaccinated Unknown 
vaccine status 
Total, all cases 51645 24354 {47} 10158 {20} 17133 {33} 
Age 51645 (100) 24354 (100) 10158 (100) 17133 (100) 
   Mean [SD]    40 [19]    36 [16]    44 [22]    45 [20] 
   Median [25%, 75%]    36 [27, 52]    34 [26, 45]    38 [26, 62]    41 [29, 59] 
Sex 51535 (100) 24320 (100) 10136 (100) 17079 (100) 
   Female    22066 [43]    10791 [44]    4312 [43]    6963 [41] 
   Male    29469 [57]    13529 [56]    5824 [57]    10116 [59] 
IMD rank (with 1 as most 
deprived and 5 as least 
deprived)* 
43525 (84) 21240 (87) 8866 (87) 13419 (78) 
   1    16800 [39]    7779 [37]    3665 [41]    5356 [40] 
   2    13057 [30]    6836 [32]    2564 [29]    3657 [27] 
   3    6838 [16]    3459 [16]    1259 [14]    2120 [16] 
   4    4045 [9]    1893 [9]    836 [9]    1316 [10] 
   5    2785 [6]    1273 [6]    542 [6]    970 [7] 
UK birth status 49820 (96) 24084 (99) 9958 (98) 15778 (92) 
   Non-UK Born    36988 [74]    18297 [76]    6874 [69]    11817 [75] 
		 15	
   UK Born    12832 [26]    5787 [24]    3084 [31]    3961 [25] 
Ethnic group 50416 (98) 24074 (99) 10024 (99) 16318 (95) 
   White    10194 [20]    3560 [15]    2695 [27]    3939 [24] 
   Black-Caribbean    1112 [2]    559 [2]    242 [2]    311 [2] 
   Black-African    8942 [18]    4620 [19]    1602 [16]    2720 [17] 
   Black-Other    462 [1]    261 [1]    80 [1]    121 [1] 
   Indian    12994 [26]    7176 [30]    2061 [21]    3757 [23] 
   Pakistani    8237 [16]    3512 [15]    1720 [17]    3005 [18] 
   Bangladeshi    2025 [4]    918 [4]    480 [5]    627 [4] 
   Chinese    601 [1]    289 [1]    101 [1]    211 [1] 
   Mixed / Other    5849 [12]    3179 [13]    1043 [10]    1627 [10] 
Calendar year 51645 (100) 24354 (100) 10158 (100) 17133 (100) 
{% all cases}(% complete within vaccine status)[% complete within category], 
 * Index of Multiple Deprivation (2010) categorised into five groups for England 
All-cause	mortality	1	
In	the	univariable	analysis	the	odds	of	death	from	any	cause	were	lower	for	BCG	vaccinated	2	 TB	cases	compared	to	unvaccinated	cases,	with	an	OR	of	0.28	(95%	CI	0.24	to	0.32,	P:	3	 <0.001)	(table	3,	see	supplementary	table	S1	for	the	full	table);	an	association	remained	4	 after	adjusting	for	confounders,	but	was	attenuated	with	an	aOR	of	0.76	(95%	CI	0.64	to	5	 0.89,	P:	0.001).	We	estimate	that	if	all	unvaccinated	cases	had	been	vaccinated	there	would	6	 have	been	on	average	19	(95%	CI	9	to	29)	fewer	deaths	per	year	during	the	study	period	7	
		 16	
(out	of	81	deaths	per	year	on	average	in	unvaccinated	cases).	Whilst	there	was	evidence	in	1	 univariable	analyses	to	suggest	all-cause	mortality	was	higher	in	persons	vaccinated	more	2	 than	10	years	prior	to	notification	of	TB	and	that	all-cause	mortality	increased	with	3	 increasing	age	group,	these	disappeared	after	adjusting	for	potential	confounders	(table	4,	4	 supplementary	table	S2).	5	
Similar	results	to	the	multivariable	analysis	were	found	using	multiply	imputed	data	for	the	6	 association	between	vaccination	status	and	all-cause	mortality	(aOR:	0.76	(95%	CI	0.61	to	7	 0.94),	P:	0.013),	but	not	for	time	since	vaccination	with	a	greatly	increased	risk	of	all-cause	8	 mortality	estimated	for	those	vaccinated	more	than	10	years	before	case	notification,	9	 compared	to	those	vaccinated	more	recently	(aOR:	12.19	(95%	CI	3.48	to	42.64),	(see	10	 online	supplementary	table	S3,	supplementary	table	S4)).	For	age	at	vaccination	results	for	11	 the	multivariable	analysis	using	multiply	imputed	data	were	comparable	to	those	found	12	 using	complete	case	analysis,	except	that	there	was	some	evidence	that	vaccination	in	13	 adolescence,	compared	to	under	1,	was	associated	with	increased,	rather	than	decreased,	14	 all-cause	mortality	(aOR:	1.57	(95%	CI	1.13	to	2.19),	supplementary	table	S5).	15	
Deaths	due	to	TB	(in	those	who	died)	16	
There	was	little	evidence	of	any	association	between	BCG	vaccination	and	deaths	due	to	TB	17	 (in	those	who	died	and	where	cause	of	death	was	known)	in	the	univariable	analysis	(table	18	 3).	The	adjusted	point	estimate	indicated	an	association	between	BCG	vaccination	and	19	 reduced	deaths	due	to	TB	(in	those	who	died)	although	the	confidence	intervals	remained	20	 wide	with	a	similar	result	found	using	multiply	imputed	data	(see	online	supplementary	21	 table	S3).	There	were	insufficient	data	to	robustly	estimate	an	association	between	deaths	22	
		 17	
due	to	TB	(in	those	who	died)	and	years	since	vaccination	or	age	at	vaccination	(table	4,	1	 supplementary	table	S2).	2	
Recurrent	TB	3	
In	both	the	univariable	and	multivariable	analysis	there	was	some	evidence	that	BCG	4	 vaccination	was	associated	with	reduced	recurrent	TB,	although	the	strength	of	the	5	 evidence	was	weakened	after	adjusting	for	confounders	(table	3).	In	the	adjusted	analysis,	6	 the	odds	of	recurrent	TB	were	lower	for	BCG	vaccinated	cases	compared	to	unvaccinated	7	 cases,	with	an	aOR	of	0.90	(95%	CI	0.81	to	1.00,	P:	0.056).	The	strength	of	the	evidence	for	8	 this	association	was	comparable	in	the	analysis	using	multiply	imputed	data	(see	online	9	 supplementary	table	S3).	There	was	little	evidence	in	the	adjusted	analysis	of	any	10	 association	between	recurrent	TB	and	years	since	vaccination	(table	4)	or	age	at	11	 vaccination	(supplementary	table	S2).	12	
Other	Outcomes	13	
After	adjusting	for	confounders	there	was	little	evidence	for	any	association	between	BCG	14	 vaccination	and	pulmonary	disease	or	positive	sputum	smear	status	(table	3);	similar	15	 results	were	found	using	multiply	imputed	data	(see	online	supplementary	table	S3).16	
		 18	
	
Table	3:	Summary	of	associations	between	BCG	vaccination	and	all	outcomes.	Cases	represents	all	notifications	with	complete	
data	and	a	given	BCG	status,	regardless	of	outcome.	Cases	with	outcome	is	similarly	defined	but	includes	only	cases	with	the	
specified	outcome.	
Outcome BCG 
vaccinated 
Univariable Multivariable 
Cases* Cases 
with 
outcome 
(%) 
OR (95% CI) P-value Cases
† 
Cases with 
outcome 
(%) 
aOR (95% CI) P-value 
All-cause 
mortality 
No 9061 566 (6) 1 <0.001 7620 473 (6) 1 0.001 
Yes 21685 394 (2) 0.28 (0.24 to 0.32)  1837
3 
334 (2) 0.76 (0.64 to 0.89)  
Death due 
to TB (in 
No 320 174 (54) 1 0.786 270 143 (53) 1 0.177 
Yes 276 147 (53) 0.96 (0.69 to 1.32)  236 126 (53) 0.76 (0.51 to 1.13)  
		 19	
those who 
died‡) 
Recurrent 
TB 
No 9991 735 (7) 1 <0.001 8502 615 (7) 1 0.056 
Yes 23963 1371 (6) 0.76 (0.70 to 0.84)  2058
4 
1177 (6) 0.90 (0.81 to 1.00)  
Pulmonary 
TB 
No 10121 5548 (55) 1 <0.001 8595 4685 (55) 1 0.769 
Yes 24289 12204 
(50) 
0.83 (0.79 to 0.87)  2078
4 
10342 (50) 0.99 (0.94 to 1.05)  
Sputum 
smear status 
- positive 
No 3910 1679 (43) 1 0.187 3367 1435 (43) 1 0.730 
Yes 9768 4074 (42) 0.95 (0.88 to 1.02)  8351 3447 (41) 1.02 (0.93 to 1.11)  
OR (95% CI): unadjusted odds ratio with 95% confidence intervals, 
 aOR (95% CI): adjusted odds ratios with 95% confidence intervals,  
* Univariable sample size for outcomes ordered as in table (% of all cases) = 30746 (60%), 596 (23%), 33954 (66%), 34410 (67%), 
13678 (26%),  
		 20	
† Multivariable sample size with outcomes ordered as in table (% of all cases) = 25993 (50%), 506 (20%), 29086 (56%), 29379 
(57%), 11718 (23%), 
 ‡ Death due to TB in those who died and where cause of death was known 
		 21	
Table	4:	Summary	of	associations	between	years	since	vaccination	and	all	outcomes	in	individuals	who	were	vaccinated.	The	
baseline	exposure	is	vaccination	≤ 10	years	before	diagnosis	compared	to	vaccination	11 +	years	before	diagnosis.	Deaths	due	to	
TB	(in	those	who	died)	had	insufficient	data	for	effect	sizes	to	be	estimated	in	both	the	univariable	and	multivariable	analysis.	
Cases	represents	all	notifications	with	complete	data	and	a	given	BCG	status,	regardless	of	outcome.	Cases	with	outcome	is	
similarly	defined	but	includes	only	cases	with	the	specified	outcome.	
Outcome Years 
since 
BCG 
Univariable Multivariable 
Cases* Cases with 
outcome 
(%) 
OR (95% CI) P-value Cases† Cases with 
outcome 
(%) 
aOR (95% CI) P-
value 
All-cause 
mortality 
≤ 10 718 5 (1) 1 0.004 554 4 (1) 1 0.897 
11+ 8106 166 (2) 2.98 (1.22 to 7.28)  7171 148 (2) 0.91 (0.24 to 3.54)  
Death due 
to TB (in 
those who 
died‡) 
≤ 10 2 2 (100) 1 - 2 2 (100) 1 - 
11+ 108 59 (55) Insufficient data  98 53 (54) Insufficient data  
		 22	
Recurrent 
TB 
≤ 10 780 22 (3) 1 0.005 613 14 (2) 1 0.515 
11+ 9172 451 (5) 1.78 (1.15 to 2.75)  8194 406 (5) 1.24 (0.63 to 2.44)  
Pulmonary 
TB 
≤ 10 770 480 (62) 1 <0.001 601 382 (64) 1 0.309 
11+ 9248 4757 (51) 0.64 (0.55 to 0.74)  8254 4232 (51) 0.87 (0.67 to 1.14)  
Sputum 
smear status 
- positive 
≤ 10 157 81 (52) 1 0.941 122 61 (50) 1 0.920 
11+ 3064 1590 (52) 1.01 (0.73 to 1.40)  2734 1405 (51) 1.02 (0.68 to 1.54)  
OR (95% CI): unadjusted odds ratio with 95% confidence intervals, aOR (95% CI): adjusted odds ratios with 95% confidence 
intervals,  
* Univariable sample size for outcomes ordered as in table (% of vaccinated cases) = 8824 (36%), 110 (28%), 9952 (41%), 10018 
(41%), 3221 (13%),  
† Multivariable sample size with outcomes ordered as in table (% of vaccinated cases) = 7725 (32%), 100 (25%), 8807 (36%), 8855 
(36%), 2856 (12%),  
‡ Death due to TB in those who died and where cause of death was known 
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Sensitivity	analysis	1	
Dropping	duplicate	recurrent	TB	notifications	increased	the	magnitude,	and	precision,	of	2	 the	effect	sizes	for	recurrent	TB,	all-cause	mortality,	and	deaths	due	to	TB	(in	those	who	3	 died)	(see	online	supplementary	table	S6).	Restricting	the	analysis	to	only	cases	that	were	4	 eligible	for	the	BCG	schools	scheme	reduced	the	sample	size	of	the	analysis	(from	an	initial	5	 study	size	of	51645,	of	which	12832	were	UK	born,	to	9943	cases	that	would	have	been	6	 eligible	for	the	BCG	schools	scheme).	With	this	reduced	sample	size,	there	was	strong	7	 evidence	in	adjusted	analyses	of	an	association	between	BCG	vaccination	and	reduced	8	 recurrent	TB,	and	evidence	of	an	association	with	decreased	all-cause	mortality	(see	online	9	 supplementary	table	S6).	10	
		 24	
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DISCUSSION	2	
Using	TB	surveillance	data	collected	in	England	we	found	that	BCG	vaccination,	prior	to	the	3	 development	of	active	TB,	was	associated	with	reduced	all-cause	mortality	and	fewer	4	 recurrent	TB	cases,	although	the	evidence	for	this	association	was	weaker.	There	was	some	5	 suggestion	that	the	association	with	all-cause	mortality	was	due	to	reduced	deaths	due	to	6	 TB	(in	those	who	died),	though	the	study	was	underpowered	to	definitively	assess	this.	We	7	 did	not	find	evidence	of	an	association	between	BCG	status	and	positive	smear	status	or	8	 pulmonary	TB.	Analysis	with	multiply	imputed	data	indicated	that	notification	10+	years	9	 after	vaccination	was	associated	with	increased	all-cause	mortality.	In	separate	analyses,	10	 there	was	some	evidence	that	vaccination	at	birth,	compared	to	at	any	other	age,	was	11	 associated	with	reduced	all-cause	mortality,	and	increased	deaths	due	to	TB	(in	those	who	12	 died).	13	
This	study	used	a	large	detailed	dataset,	with	coverage	across	demographic	groups,	and	14	 standardized	data	collection	from	notifications	and	laboratories.	The	use	of	routine	15	 surveillance	data	means	that	this	study	would	be	readily	repeatable	with	new	data.	The	16	 surveillance	data	contained	multiple	known	risk	factors,	this	allowed	us	to	adjust	for	these	17	 confounders	in	the	multivariable	analysis,	which	attenuated	the	evidence	for	an	association	18	 with	BCG	vaccination	for	all	outcomes.	However,	there	are	important	limitations	to	19	 consider.	The	study	was	conducted	within	a	population	of	active	TB	cases,	therefore	the	20	 association	with	all-cause	mortality	cannot	be	extrapolated	to	the	general	population.	21	 Additionally,	vaccinated	and	unvaccinated	populations	may	not	be	directly	comparable	22	 because	vaccination	has	been	targeted	at	high-risk	neonates	in	the	UK	since	2005.	We	23	
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mitigated	this	potential	source	for	bias	by	conducting	a	sensitivity	analysis	including	only	1	 those	eligible	for	the	universal	school	age	scheme,	and	whilst	the	strength	of	associations	2	 were	attenuated	there	remained	some	evidence	of	improved	outcomes.	Sensitivity	analysis	3	 excluding	recurrent	cases	indicated	their	inclusion	may	have	biased	our	results	towards	4	 the	null.	5	
Variable	data	completeness	changed	with	time,	with	both	BCG	vaccination	status	and	year	6	 of	vaccination	having	a	high	percentage	of	missing	data,	which	may	not	be	missing	7	 completely	at	random.	We	therefore	checked	the	robustness	of	our	results	with	multiple	8	 imputation	including	regional	variability,	however	an	unknown	missing	not	at	random	9	 mechanism,	or	unmeasured	confounding	may	still	have	introduced	bias.	We	found	a	greatly	10	 increased	risk	of	all-cause	mortality	for	those	vaccinated	more	than	10	years	ago	in	the	11	 analysis	with	multiply	imputed	data,	compared	to	the	complete	case	analysis.	This	is	likely	12	 to	be	driven	by	a	missing	not	at	random	mechanism	for	years	since	vaccination,	with	older	13	 cases	being	both	more	likely	to	have	been	vaccinated	more	than	10	years	previously	and	to	14	 also	have	an	unknown	year	of	vaccination.	The	high	percentage	of	missing	data	also	means	15	 that	we	were	likely	to	be	underpowered	to	detect	an	effect	of	BCG	vaccination	on	sputum	16	 smear	status	and	deaths	due	to	TB	(in	those	who	died),	with	years	since	vaccination,	and	17	 age	at	vaccination	likely	to	be	underpowered	for	all	outcomes.	We	were	not	able	to	adjust	18	 for	either	tuberculin	skin	test	(TST)	stringency,	or	the	latitude	effect,	although	we	were	19	 able	to	adjust	for	UK	birth	status.[29]	However,	the	bias	induced	by	these	confounders	is	20	 likely	to	be	towards	the	null,	meaning	that	our	effect	estimates	are	likely	to	be	conservative.	21	 We	could	also	not	adjust	for	the	BCG	strain	each	individual	may	have	received,	the	BCG	22	 strain	used	may	vary	both	temporally	and	geographically.	Finally,	BCG	vaccination	status,	23	
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and	year	of	vaccination,	may	be	subject	to	misclassification	due	to	recall	bias;	validation	1	 studies	of	the	recording	of	BCG	status	in	the	ETS	would	be	required	to	assess	this.	2	
Little	work	has	been	done	to	assess	the	overall	effect	of	BCG	on	outcomes	for	active	TB	3	 cases	although	the	possible	non-specific	effects	of	BCG	are	an	area	of	active	4	 research.[14,30,31]	Whilst	multiple	studies	have	investigated	BCG’s	association	with	all-5	 cause	mortality,	it	has	been	difficult	to	assess	whether	the	association	continues	beyond	6	 the	first	year	of	life.[31]	The	effect	size	of	the	association	we	identified	between	BCG	and	7	 all-cause	mortality	in	active	TB	cases	was	comparable	to	that	found	in	a	Danish	case-cohort	8	 study	in	the	general	population	(aHR:	0.58	(95%	CI	0.39	to	0.85).[16]	A	recent	systematic	9	 review	also	found	that	BCG	vaccination	was	associated	with	reduced	all-cause	mortality	in	10	 neonates,	with	an	average	relative	risk	of	0.70	(95%	CI	0.49	to	1.01)	from	five	clinical	trials	11	 and	0.47	(95%	CI	0.32	to	0.69)	from	nine	observational	studies	at	high	risk	of	bias.[14]	We	12	 found	some	weak	evidence	that	BCG	vaccination	was	associated	with	reduced	deaths	due	13	 to	TB	(in	those	who	died),	although	our	point	estimate	had	large	confidence	intervals.	14	 Several	meta-analyses	have	found	evidence	supporting	this	association,[6,15]	with	one	15	 meta-analysis	estimating	a	71%	(RR:	0.29	95%	CI	0.16	to	0.53)	reduction	in	deaths	due	to	16	 TB	in	individuals	vaccinated	with	BCG.[6]	The	meta-analysis	performed	by	Abubakar	et	17	 al.	also	found	consistent	evidence	for	this	association,	with	a	Rate	Ratio	of	0.22	(95%	CI	18	 0.15	to	0.33).[15]	In	contrast	to	our	study,	both	of	these	meta-analyses	estimated	the	19	 protection	from	TB	mortality	in	BCG	vaccinated	individuals	rather	than	in	BCG	vaccinated	20	 cases	who	had	died	from	any	cause.	Additionally,	neither	study	explored	the	association	21	 between	BCG	vaccination	and	all-cause	mortality	or	recurrent	TB.	This	study	could	not	22	 determine	the	possible	causal	pathway	for	the	association	between	BCG	vaccination	all-23	
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cause	mortality,	and	recurrent	TB.	These	are	important	to	establish	in	order	to	understand	1	 the	effect	of	BCG	vaccination	on	TB	outcomes.	2	
We	found	that	BCG	vaccination	was	associated	with	reduced	all-cause	mortality,	with	some	3	 weaker	evidence	of	an	association	with	reduced	recurrent	TB.	A	plausible	mechanism	for	4	 this	association	is	that	BCG	vaccination	improves	treatment	outcomes,[12]	which	then	5	 results	in	decreased	mortality,	and	reduced	recurrent	TB.	However,	these	effects	may	also	6	 be	independent	and	for	all-cause	mortality	may	not	be	directly	related	to	active	TB.	In	this	7	 case,	a	possible	mechanism	for	the	association	between	BCG	vaccination	and	all-cause	8	 mortality	is	that	BCG	vaccination	modulates	the	innate	immune	response,	resulting	in	non-9	 specific	protection.[11]	For	low	incidence	countries,	where	the	reduction	in	TB	cases	has	10	 been	used	as	evidence	to	scale	back	vaccination	programs,[7]	these	results	suggest	that	11	 BCG	vaccination	may	be	more	beneficial	than	previously	thought.	In	countries	that	target	12	 vaccination	at	those	considered	to	be	at	high	risk	of	TB	the	results	from	this	study	could	be	13	 used	to	help	drive	uptake	by	providing	additional	incentives	for	vaccination.	The	evidence	14	 we	have	presented	should	be	considered	in	future	cost-effectiveness	studies	of	BCG	15	 vaccination	programs.	16	
Further	work	is	required	to	determine	whether	years	since	vaccination	and	age	at	17	 vaccination	are	associated	with	TB	outcomes	as	this	study	was	limited	by	low	sample	size,	18	 missing	data	for	year	of	vaccination,	and	the	relative	rarity	of	some	TB	outcomes.	However,	19	 due	to	the	continuous	collection	of	the	surveillance	data	used	in	this	analysis,	this	study	20	 could	be	repeated	once	additional	data	have	been	collected.	If	this	study	were	to	be	21	 repeated	with	a	larger	sample	size	particular	attention	should	be	given	to	the	functional	22	
		 28	
form	of	any	decay	in	protection	from	negative	TB	outcomes.	Additionally,	a	larger	sample	1	 size	would	allow	investigation	of	the	associations	identified	between	TB	outcomes	and	BCG	2	 vaccination	stratified	by	pulmonary,	extrapulmonary,	and	disseminated	TB	disease.	3	 Between	country	variations	in	the	strength	of	associations	could	also	be	explored	as	a	4	 proxy	to	BCG	strain	using	sub-group	analysis.	The	results	from	this	study	require	validation	5	 in	independent	datasets	and	the	analysis	should	be	reproducible	in	other	low	incidence	6	 countries	that	have	similarly	developed	surveillance	systems.	If	validated	in	low	incidence	7	 countries,	similar	studies	in	medium	to	high	incidence	countries	should	be	conducted	8	 because	any	effect	would	have	a	greater	impact	in	these	settings.	9	
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